KRRO · Korro Bio, Inc.

Summary

Korro Bio, Inc. entered into a subscription agreement on March 9, 2026, to sell 4,501,928 shares of common stock at $11.11 per share and pre-funded warrants for 3,148,836 shares at $11.109 per warrant in a private placement, expecting approximately $85 million in gross proceeds before fees. The financing, led by Venrock Healthcare Capital Partners, extends cash runway into the second half of 2028 to advance RNA editing pipeline programs.

Key takeaways

• Subscription agreement dated March 9, 2026, with institutional accredited investors
• 4,501,928 common shares at $11.11 per share
• 3,148,836 pre-funded warrants at $11.109 each, exercisable at $0.001 per share with 9.99% beneficial ownership blocker
• Gross proceeds ~$85 million, closing expected March 10, 2026
• Led by Venrock Healthcare Capital Partners; participants include ADAR1 Capital Management, Affinity Asset Advisors, Balyasny Asset Management, Driehaus Capital Management, Kalehua Capital, Lynx1 Capital Management, Nantahala Capital, New Enterprise Associates
• Cash position $85.2 million as of Dec 31, 2025; net proceeds fund pipeline advancement into H2 2028
• Placement agents: Citigroup, Cantor, Oppenheimer & Co., William Blair